Aardvark Therapeutics (AARD) Short-term Investments (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Short-term Investments data on file, last reported at $28.8 million in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments fell 76.94% year-over-year to $28.8 million; the trailing twelve-month figure through Mar 2026 stood at $28.8 million (down 76.94% YoY), and the FY2025 full-year result was $63.0 million, up 423.84% from the prior year.
• Short-term Investments retreated to $28.8 million in Q1 2026, from $63.0 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $124.8 million in Q1 2025 to a low of $12.0 million in Q4 2024.
• A 3-year average of $71.9 million and a median of $75.0 million in 2025 frame the typical range for Short-term Investments.
• Across the five-year window, Short-term Investments surged 423.84% in 2025 and sank 76.94% in 2026, its largest moves.
• Tracing AARD's Short-term Investments over 3 years: stood at $12.0 million in 2024, then surged by 423.84% to $63.0 million in 2025, then sank by 54.33% to $28.8 million in 2026.
• Business Quant data shows AARD's Short-term Investments at $28.8 million in Q1 2026, $63.0 million in Q4 2025, and $87.1 million in Q3 2025.